Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHRH1SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC6A2
The experimentally established mechanism targets of Orphenadrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.97 |
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.97 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.97 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.97 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.97 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.97 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.97 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.97 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.97 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.71 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.71 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.71 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orphenadrine SCHEMBL30903909 | 1.00 | LMNA (1.00) | LMNAPMP22BLMNPSR1SLC6A2 | |
| Orphenadrine SCHEMBL119471 | 0.98 | SLC6A2 (1.00) | LMNAPMP22BLMNPSR1SLC6A2 | |
| Orphenadrine SCHEMBL29359844 | 0.98 | SLC6A2 (1.00) | LMNAPMP22BLMNPSR1SLC6A2 | |
| Orphenadrine SCHEMBL28727 | 0.98 | SLC6A2 (1.00) | LMNAPMP22BLMNPSR1SLC6A2 | |
| Orphenadrine SCHEMBL4338150 | 0.95 | SLC6A2 (0.94) | LMNAPMP22BLMNPSR1SLC6A2 | |
| Hydrochloric Acid SCHEMBL29519368 | 0.91 | LMNA (0.84) | LMNAPMP22BLMNPSR1SLC6A2 | |
| Hydrochloric Acid SCHEMBL29519484 | 0.88 | LMNA (0.78) | LMNAPMP22BLMNPSR1SLC6A2 | |
| SCHEMBL2615259 | 0.87 | SLC6A2 (0.79) | LMNAPMP22BLMNPSR1SLC6A2 | |
| SCHEMBL637495 | 0.87 | SLC6A2 (0.78) | LMNAPMP22BLMNPSR1SLC6A2 | |
| Diphenhydramine SCHEMBL17071 | 0.85 | LMNA (1.00) | LMNAPMP22BLMNPSR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724114-A1 | CYANOACRYLATE ADHESIVE KITS | Chemence, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| WO-2026041855-A1 | CYANOACRYLATE ADHESIVE KITS | CHEMENCE, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| US-20200131431-A1 | CHEMICAL ADDITIVES AND SURFACTANT COMBINATIONS FOR FAVORABLE WETTABILITY ALTERATION AND IMPROVED HYDROCARBON RECOVERY FACTORS | ALCHEMY SCIENCES INC (US) | 2020-04-30 | — | — | US | claimed |
| US-20190133924-A1 | Alcohol-Resistant Formulations | CIMA LABS INC (US) | 2019-05-09 | — | — | US | claimed |
| US-10154856-B2 | Therapeutic substance transfer catheter and method | SILLENDER MARK (AU) | 2018-12-18 | — | — | US | claimed |
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| US-20150359566-A1 | THERAPEUTIC SUBSTANCE TRANSFER CATHETER AND METHOD | SILLENDER MARK (US) | 2015-12-17 | — | — | US | claimed |
| EP-2953678-A1 | THERAPEUTIC SUBSTANCE TRANSFER CATHETER AND METHOD | Sillender, Mark (AU) | 2015-12-16 | — | — | EP | claimed |
| WO-2014121332-A1 | THERAPEUTIC SUBSTANCE TRANSFER CATHETER AND METHOD | SILLENDER MARK (AU) | 2014-08-14 | — | — | WO | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| EP-1476195-A2 | ENHANCEMENT OF THE ACTION OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS | PITMY INTERNATIONAL N.V. (AN) | 2004-11-17 | — | — | EP | claimed |
| WO-2002005851-A2 | ENHANCEMENT OF THE ACTION OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS | PITMY INTERNATIONAL N.V. (AN) | 2002-01-24 | — | — | WO | claimed |
| US-5045454-A | Iron chelate, aurintricarboxylic acid, and chelate compounds | MEDI-CULT A/S (DK) | 1991-09-03 | — | — | US | claimed |
| US-4244941-A | POROUS COATING OF COMPRESSED POWDERS ALLOWS CONSTANT RELEASE OF CORE SUBSTANCE | GIST-BROCADES N.V. (NL) | 1981-01-13 | — | — | US | claimed |
| EP-4724114-A1 | CYANOACRYLATE ADHESIVE KITS | Chemence, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2026041855-A1 | CYANOACRYLATE ADHESIVE KITS | CHEMENCE, INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| US-20260014136-A1 | LIPOPHILIC ACTIVE ORAL FILM FORMULATION AND METHOD OF MAKING THE SAME | INTELGENX CORP (CA) | 2026-01-15 | — | — | US | disclosed |
| EP-0055043-A2 | 6,7,8,9-Tetrahydro-3H-benz(e)indolamine derivatives, processes for their preparation and intermediates used therein, and pharmaceutical compositions containing the indolamine derivatives | AYERST, MCKENNA AND HARRISON INC. (CA) | 1982-06-30 | — | — | EP | disclosed |
| EP-0034894-A2 | 2-(1-Piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives, processes for their preparation, intermediates used in the processes and the preparation thereof and pharmaceutical compositions containing the derivatives | AYERST, MCKENNA AND HARRISON INC. (CA) | 1981-09-02 | — | — | EP | disclosed |
| US-4244941-A | POROUS COATING OF COMPRESSED POWDERS ALLOWS CONSTANT RELEASE OF CORE SUBSTANCE | GIST-BROCADES N.V. (NL) | 1981-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014136-A1 | LIPOPHILIC ACTIVE ORAL FILM FORMULATION AND METHOD OF MAKING THE SAME | MGLL, NPC1L1, LIPA | SLC6A2 1076/4885HRH1 1219/4885GRIN2D 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.